کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3263227 1207755 2012 6 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Clinical profile and predictors of mortality in patients of acute-on-chronic liver failure
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی غدد درون ریز، دیابت و متابولیسم
پیش نمایش صفحه اول مقاله
Clinical profile and predictors of mortality in patients of acute-on-chronic liver failure
چکیده انگلیسی

BackgroundAcute-on-chronic liver failure (ACLF) is characterised by acute hepatic insult manifesting as jaundice and coagulopathy, complicated within 4 weeks by ascites and/or encephalopathy in patients with previously diagnosed or undiagnosed chronic liver disease. We studied the clinical, biochemical and etiological profiles of ACLF patients investigating variables which could predict mortality.MethodsConsecutive ACLF patients were enrolled and given standard intensive care management. They were monitored for predictors of 90-day mortality.Results91 patients were included; besides jaundice (median bilirubin 23.1 mg/dL) and coagulopathy, acute onset ascites with or without encephalopathy was the presenting symptom in 92%. In all patients a first diagnosis of chronic liver disease was made, mainly due to hepatitis B (37%) or alcohol (34%). Reactivation of chronic hepatitis B and alcoholic hepatitis were the common acute insults. The 90-day mortality was 63%. On multivariate analysis, hepatic encephalopathy, low serum sodium, and high INR were found to be independent baseline predictors of mortality. Amongst all severity scores studied, MELD, SOFA and APACHE-II scores had AUROCs of >0.8 which was significantly higher than that of Child–Turcotte–Pugh.ConclusionsACLF has very high mortality. Hepatic encephalopathy, low serum sodium and high INR predict poor outcome. Mortality can also be predicted by baseline MELD, SOFA or APACHE-II scores.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Digestive and Liver Disease - Volume 44, Issue 2, February 2012, Pages 166–171
نویسندگان
, , , , , ,